Advocates for rare-disease patients, mental health and addictions services, and home and community care are raising alarm as a cluster of federal-provincial bilateral funding agreements approaches their March 2027 expiry with no public commitment from Ottawa on renewal. <cite index=”12-1″>With less than nine months remaining until the deals lapse, advocates say they do not know whether the funding will continue, and are increasingly worried about the consequences of losing it.</cite> <cite index=”13-1″>Health Minister Marjorie Michel’s office has confirmed only that talks are underway to renew the “Working Together” health workforce agreements, while declining to comment on the broader set of deals covering medicines for rare diseases and seniors’ care that were introduced under the previous Liberal government.</cite>
The stakes are substantial. <cite index=”15-1″>Internal projections show Health Canada could see spending drop by more than $3 billion over the next three years if the rare-disease drug strategy, the Canadian Drugs and Substances Strategy, and home care and mental health funding are not renewed — a reduction tied to both a federal spending review and the natural sunset of programs launched under the prior government.</cite> <cite index=”19-1″>The rare-disease drug strategy alone represents up to $1.4 billion committed to provinces and territories to improve coverage of and access to new and existing drugs for rare conditions and to strengthen screening and diagnostics.</cite>
For a health system that has come to depend on these bilateral transfers to fund services provincial budgets alone would not sustain, the ambiguity is itself a policy problem: provinces, clinics and patient organizations cannot plan multi-year programming — particularly in mental health and home care — without knowing whether federal dollars will still be flowing past next March. This is a story worth tracking closely through the fall fiscal update.
Source: The Hill Times